Physician profile
Patrick Gainey
NPI 1306880240
$1,192.58
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2021: $238 · 2022: $395.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $373.94 | 2019-2022 | |
| Abbvie INC. | $180.76 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $129.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.07 | 2019 | |
| Emd Serono, INC. | $112.40 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $107.44 | 2021 | |
| Lilly USA, LLC | $82.67 | 2019 | |
| Biogen, INC. | $19.33 | 2019 | |
| Allergan, INC. | $19.06 | 2021 | |
| Ge Healthcare | $18.07 | 2019 | |
| Pfizer INC. | $13.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.